JANX Stock Overview
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Janux Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$48.21 |
| 52 Week High | US$58.69 |
| 52 Week Low | US$5.65 |
| Beta | 4.18 |
| 1 Month Change | 25.12% |
| 3 Month Change | 401.14% |
| 1 Year Change | 229.98% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 91.69% |
Recent News & Updates
Recent updates
Janux Therapeutics: A Prime Target In Cancer Care's M&A Game
Apr 11Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024
Feb 27Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth
Feb 24
Is Janux Therapeutics, Inc. (NASDAQ:JANX) Trading At A 37% Discount?
Dec 29Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans
Nov 04We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely
Jul 20A Look At The Intrinsic Value Of Janux Therapeutics, Inc. (NASDAQ:JANX)
May 23Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation
Feb 09We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth
Oct 19Janux Therapeutics GAAP EPS of -$0.41, revenue of $2.37M
Aug 09We Think Janux Therapeutics (NASDAQ:JANX) Can Easily Afford To Drive Business Growth
Jun 05Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans
Feb 19Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation
Nov 03Shareholder Returns
| JANX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.5% | 1.0% | 1.2% |
| 1Y | 230.0% | 0.7% | 24.9% |
Return vs Industry: JANX exceeded the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: JANX exceeded the US Market which returned 24.7% over the past year.
Price Volatility
| JANX volatility | |
|---|---|
| JANX Average Weekly Movement | 65.9% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: JANX's share price has been volatile over the past 3 months.
Volatility Over Time: JANX's weekly volatility has increased from 34% to 66% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 64 | David Campbell | www.januxrx.com |
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company’s clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products.
Janux Therapeutics, Inc. Fundamentals Summary
| JANX fundamental statistics | |
|---|---|
| Market cap | US$2.57b |
| Earnings (TTM) | -US$58.29m |
| Revenue (TTM) | US$8.08m |
308.1x
P/S Ratio-42.7x
P/E RatioIs JANX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JANX income statement (TTM) | |
|---|---|
| Revenue | US$8.08m |
| Cost of Revenue | US$7.87m |
| Gross Profit | US$210.00k |
| Other Expenses | US$58.50m |
| Earnings | -US$58.29m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.13 |
| Gross Margin | 2.60% |
| Net Profit Margin | -721.18% |
| Debt/Equity Ratio | 0% |
How did JANX perform over the long term?
See historical performance and comparison